EyePoint Pharma 
Welcome,         Profile    Billing    Logout  
 6 Products   5 Diseases   6 Products   15 Trials   651 News 


«123456»
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    V06 - The Capsular Bag: A New Site for Drug Delivery (Morial Convention Center) -  Oct 20, 2021 - Abstract #AAO2021AAO_2103;    
    This study evaluating the injection of Dexycu into a new location, the capsular bag, proved very promising. It was conducted independently and without support of the manufacturer.
  • ||||||||||  Dextenza (dexamethasone punctal plug) / Ocular Therap, Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Utilization and Cost-Analysis of Novel Dropless Steroid Alternatives for Cataract Surgery Among Medicare Beneficiaries (Morial Convention Center) -  Oct 20, 2021 - Abstract #AAO2021AAO_1659;    
    Conclusion Dropless dexamethasone delivery technologies address patient inconvenience and poor compliance but entail disproportionately high costs compared to traditional steroid drops. This may explain the low adoption rates of these new drug delivery technologies, despite their pass-through status.
  • ||||||||||  Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
    Journal:  Yutiq - another fluocinolone intravitreal implant for uveitis. (Pubmed Central) -  Sep 30, 2021   
    This may explain the low adoption rates of these new drug delivery technologies, despite their pass-through status. No abstract available
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Journal:  Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis. (Pubmed Central) -  Sep 11, 2021   
    The efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema (UME) was assessed on twenty-six patients (34 eyes) with non-infectious UME between 2013 and 2020, in a mean follow-up of 18 ± 19.3 (mean ± SD) months...There was an overall increase in intraocular pressure (IOP; +4.4 ± 3.7 mmHg) and eye drops were required in three eyes. The FAc implant led to long-term improvements in mean CRT and VA, and that the side-effect profile was manageable in a clinical setting in patients with non-infectious UME.
  • ||||||||||  Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
    Enrollment open, Surgery:  A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery (clinicaltrials.gov) -  Aug 26, 2021   
    P1,  N=5, Recruiting, 
    The FAc implant led to long-term improvements in mean CRT and VA, and that the side-effect profile was manageable in a clinical setting in patients with non-infectious UME. Not yet recruiting --> Recruiting
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / AbbVie, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Journal:  Treatment of radiation-induced maculopathy with fluocinolone acetonide. (Pubmed Central) -  Aug 20, 2021   
    Slow-release implants of FAc are a promising therapeutic potent steroid treatment option to benefit anatomical structures of the fovea and visual function. Slow-release implants with FAc reduce the frequency of intravitreal injections and the therapeutic burden.
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Capsular Bag: A New Site for Drug Delivery () -  Jul 19, 2021 - Abstract #ASCRSASOA2021ASCRS_ASOA_74;    
    While VR surgeons have enjoyed innovation in drug delivery, cataract surgeons have had to accept topical therapy for decades despite disadvantages. This independent study evaluated the injection of Dexycu into a new location, the capsular bag.
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Review, Journal:  Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review. (Pubmed Central) -  Jun 1, 2021   
    The 0.19 mg fluocinolone acetonide (FAc) implant (Iluvien®) releases FAc for 36 months, and it is approved for the treatment of diabetic macular edema (DME) and noninfectious uveitis...FAc implant may be a potential treatment for these diseases; however, the level of scientific evidence of the included studies in this review is limited. Further studies with larger cohorts and longer follow-ups are needed to validate this data.
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    [VIRTUAL] The ILUVIEN implant in DME – are we leaving it too late? () -  May 13, 2021 - Abstract #ARVO2021ARVO_3086;    
    These results could help optimise future management plans for DME. Limitations of the study include being retrospective and the differences in baseline characteristics that may have impacted on results.
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    [VIRTUAL] Effect of Dexamethasone Intracameral Drug-Delivery Suspension on Macular Thickness after Vitreoretinal Surgery () -  May 13, 2021 - Abstract #ARVO2021ARVO_2704;    
    Intracameral dexamethasone drug-delivery suspension placed in the anterior chamber after vitreoretinal surgery was associated with a significant reduction in macular thickness up to 12 weeks following vitreoretinal surgery, whereas patients receiving daily topical corticosteroids demonstrated significantly more OCT MT at 4 and 8 weeks post-operatively. These results indicate a greater benefit of intracameral dexamethasone drug-delivery suspension for preventing post-operative causes of increased macular thickness including cystoid macular edema compared to topical anti-inflammatory treatment among patients undergoing vitreoretinal surgery.
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Clinical, Journal:  The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema. (Pubmed Central) -  May 6, 2021   
    Retro-IDEAL was a 3-year retrospective, multicenter study in patients with chronic DME (i.e. DME that persists or recurs despite treatment) treated with ILUVIEN (0.2 µg daily fluocinolone acetonide intravitreal implant), who had suboptimal outcomes with first-line vascular endothelial growth-factor inhibitors and other DME therapies...These long-term data suggest that the 0.2 μg/day FAc implant is effective in both vitrectomized and non-vitrectomized patients, with a manageable safety profile, and improved VA and reduced supplemental therapies for patients with a suboptimal response to first-line DME therapies. Clinicians may consider utilizing the FAc implant earlier in the DME disease process.
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Clinical, Journal:  Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema. (Pubmed Central) -  Apr 30, 2021   
    The Iluvien Clinical Evidence cohort study in the United Kingdom (ICE-UK) investigated the effectiveness of the FAc implant in people treated at 13 hospitals from April 2013 to April 2015...There might be VA benefits in reducing variability in CFT over time. This merits further exploration but would require more frequent CFT observations in order to properly determine patterns of retinal thickness variability.
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / AbbVie, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    NICE, Review, Journal:  Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) -  Apr 2, 2021   
    The National Institute for Health and Care Excellence (NICE) invited Alimera Sciences, the company manufacturing fluocinolone acetonide intravitreal implant (FAc) 0.19 mg (tradename ILUVIEN), to submit evidence on the clinical and cost-effectiveness of FAc for treating recurrent non-infectious uveitis...There was no comparison of FAc to any treatment listed in the final scope, and especially to the dexamethasone intravitreal implant (dexamethasone), which was considered to be a relevant comparator by the AC...After a second AC meeting where alternative company scenarios comparing FAc with dexamethasone were considered by the AC, the AC concluded that "the results of the company's analyses ranged from the fluocinolone acetonide implant being dominant (that is, it was more effective and costs less), to an ICER of £29,461 per QALY gained, and most of the ICERs were below £20,000 per QALY gained". Therefore, the AC recommended FAc as a cost-effective use of National Health Service (NHS) resources for treating recurrent non-infectious uveitis affecting the posterior segment of the eye in the final TA590 guidance (published July 2019).
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Advances in intravitreal therapy and implants: where are we now? (Pubmed Central) -  Mar 13, 2021   
    Therefore, the AC recommended FAc as a cost-effective use of National Health Service (NHS) resources for treating recurrent non-infectious uveitis affecting the posterior segment of the eye in the final TA590 guidance (published July 2019). No abstract available
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Trial completion:  Effect of Intraoperative Dexamethasone on Post-op Dry Eye (clinicaltrials.gov) -  Jan 29, 2021   
    P4,  N=40, Completed, 
    No abstract available Active, not recruiting --> Completed
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Trial completion, Phase classification, Surgery:  A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% (clinicaltrials.gov) -  Dec 11, 2020   
    P4,  N=31, Completed, 
    This potentially offers an alternative approach to complex cases that show good response to short-term corticosteroid use. Recruiting --> Completed | Phase classification: P2 --> P4
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    [VIRTUAL] PA053: Three-Year Real-World Outcomes From the IRISS Registry Study, Using the 0.2 µg/day FAc Implant () -  Nov 11, 2020 - Abstract #AAO2020AAO_807;    
    Outcomes from the IRISS Registry for the fluocinolone acetonide (FAc) implant (Iluvien) were examined to assess whether the randomized controlled trial (RCT) findings could be reproduced in clinical practice...Conclusion Results from the IRISS Registry study show similar outcomes to those reported in FAME. VA remained stable throughout a 3-year period in patients with a good starting VA (=70 letters), and better VA outcomes were experienced in FAc-treated patients when treated earlier in the disease.
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    [VIRTUAL] PO399: Outcomes From the Prospective IDEAL Registry Study: Results Achieved With the 0.2 μg/Day FAc Implant () -  Nov 11, 2020 - Abstract #AAO2020AAO_718;    
    Purpose There are limited prospectively collected data for the fluocinolone acetonide (FAc; Iluvien) implant, and so the German IDEAL registry study was designed to assess this gap in the literature...IOP (15.7 ± 3.3 mmHg at baseline; n = 175) remained relatively stable during the follow-up period, with 26.7% of eyes requiring IOP-lowering drops and 0.53% required IOP-lowering surgery. Conclusion Prospective treatment with the FAc implant in real German practices led to marked improvements in CMT and the stabilization of BCVA over a 24-month period.